Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs Physician's Choice in Advanced Colorectal Cancer
NCT06199973Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan in colorectal cancer (CRC) (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Progression-Free Survival assessed by Independent Review Committee up to 3 years. Started Mar 2024; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06199973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199973.